By Chris Wack

Agenus Inc. on Tuesday reported the triggering of a $15.1 million milestone payment from HealthCare Royalty Partners based on sales of GlaxoSmithKline's Shingrix vaccine exceeding $2 billion in 2019.

Agenus said its proprietary QS-21 Stimulon is a key component in GlaxoSmithKline's Shingrix vaccine, which has generated sales exceeding $2.3 billion in its second year after launch.

Agenus said it is due another milestone amounting to $25.5 million if Shingrix sales exceed $2.75 billion over four consecutive quarters before 2026.

Agenus shares were up 6% to $2.49 in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

March 10, 2020 09:39 ET (13:39 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Gsk
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Gsk